Related Experiment Video

Updated: Nov 18, 2025

Live-3D-Cell Immunocytochemistry Assays of Pediatric Diffuse Midline Glioma
09:06

Live-3D-Cell Immunocytochemistry Assays of Pediatric Diffuse Midline Glioma

Published on: November 11, 2021

2.8K

Double-targeting CDCA8 and E2F1 inhibits the growth and migration of malignant glioma

Xiaoxiong Wang1,2, Heping Wang3, Jiajun Xu1,2

  • 1Department of Neurosurgery, The First Affiliated Hospital of Harbin Medical University, No. 23 Youzheng Street, Nangang District, 150001, Harbin, Heilongjiang Province, People's Republic of China.

Cell Death & Disease
|February 5, 2021
PubMed

Insights

High-grade glioma malignancy is promoted by Cell Division Cycle Associated 8 (CDCA8), which enhances proliferation and migration. Targeting CDCA8 and its partner E2F1 offers new therapeutic strategies for aggressive brain tumors.

Area of Science:

  • Oncology
  • Molecular Biology
  • Neuroscience

Background:

  • High-grade glioma is an aggressive primary brain tumor with limited treatment options.
  • Cell Division Cycle Associated 8 (CDCA8) is a known regulator of the cell cycle and a promoter of various cancers.
  • The specific role of CDCA8 in glioma pathogenesis remains largely uncharacterized.

Purpose of the Study:

  • To investigate the biological role and clinical significance of CDCA8 in high-grade glioma.
  • To elucidate the mechanisms by which CDCA8 influences glioma progression.
  • To identify CDCA8 as a potential therapeutic target and prognostic biomarker for glioma.

Main Methods:

  • Correlation analysis of CDCA8 expression levels with clinical parameters (WHO grade, survival).
  • In vitro cell culture experiments to assess proliferation, migration, and apoptosis.
  • In vivo xenograft models to evaluate tumor growth and malignancy.
  • Gene microarray analysis to identify interacting proteins.

Main Results:

  • Elevated CDCA8 levels significantly correlate with advanced WHO grade and poorer overall and disease-free survival in glioma patients.
  • CDCA8 overexpression promotes glioma cell proliferation and migration while inhibiting apoptosis in vitro and in vivo.
  • Gene microarray analysis identified E2F1 as a synergistic protein partner of CDCA8.
  • CDCA8 and E2F1 together facilitate glioma cell proliferation and migration.

Conclusions:

  • CDCA8 plays a crucial role in promoting high-grade glioma malignancy.
  • The synergistic interaction between CDCA8 and E2F1 drives glioma progression.
  • CDCA8 represents a promising therapeutic target and prognostic biomarker for malignant glioma.

More Related Videos

Flow Cytometry-based Drug Screening System for the Identification of Small Molecules That Promote Cellular Differentiation of Glioblastoma Stem Cells10:28

Flow Cytometry-based Drug Screening System for the Identification of Small Molecules That Promote Cellular Differentiation of Glioblastoma Stem Cells

Published on: January 10, 2018

8.5K
A Simple Guide Screw Method for Intracranial Xenograft Studies in Mice08:11

A Simple Guide Screw Method for Intracranial Xenograft Studies in Mice

Published on: September 26, 2011

23.5K

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.1K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.3K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.0K